

ESMO 2018 Industry Satellite Symposium

EGFR-mutated NSCLC:

A data-driven approach to optimising patient outcomes

ICM – Room 14b, Messe Munich
Munich, Germany
Sunday 21 October 2018, 13.00–14.30

Chair: Jürgen Wolf (Germany)

Agenda

First-line treatment of patients with EGFR-mutated advanced NSCLC
Suresh Ramalingam (USA)

The importance of biomarker testing in identifying optimal treatments in advanced NSCLC
David Gonzalez de Castro (UK)

Treatment options after disease progression on an EGFR-TKI
Myung-Ju Ahn (South Korea)

Panel discussion: Optimal treatment sequencing in EGFR-mutated advanced NSCLC
Faculty

Audience Q&A
Faculty and audience

Light refreshments are available prior to the symposium